Psoriatic Arthritis Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Psoriatic Arthritis market is estimated to be valued at USD 6.8 billion in 2025 and is expected to reach USD 11.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032. This robust growth reflects increasing prevalence, improved diagnostic methods, and expanding therapeutic options, positioning the market for significant expansion over the forecast period.

Current market trends emphasize advancements in biologic therapies and targeted treatments, which are driving demand and improving patient outcomes. Additionally, growing awareness about psoriatic arthritis among healthcare providers and patients, coupled with increased investments in research and development, is accelerating innovation. The integration of digital health technologies for disease management further supports these positive market dynamics, fostering enhanced treatment adherence and personalized care approaches.

Segmental Analysis:

By Drug Class: Dominance of Biologics Driven by Targeted Therapeutics and Efficacy

In terms of By Drug Class, Biologics contributes the highest share of the Psoriatic Arthritis market owing to their targeted mechanisms of action and superior clinical efficacy compared to traditional therapies. Biologics are engineered to specifically inhibit key inflammatory pathways involved in the pathogenesis of psoriatic arthritis, such as tumor necrosis factor-alpha (TNF-α), interleukins (IL-12/23, IL-17), and other cytokines. This precision targeting results in more effective control of symptoms, slowing disease progression, and improving patients' quality of life, which has made biologics the preferred treatment option among clinicians and patients alike.

Additionally, ongoing innovations and approvals of new biologic agents with better safety profiles and ease of administration, including subcutaneous injections and less frequent dosing schedules, have significantly contributed to their market prominence. The ability of biologics to address both joint and skin manifestations comprehensively positions them as a multi-dimensional treatment, further solidifying their adoption. Meanwhile, competitive pricing strategies facilitated by biosimilars entering the market have enhanced accessibility, broadening their patient base. In contrast, other drug classes such as small molecule therapies and conventional DMARDs continue to play an important role, especially for patients with mild to moderate disease or those who may not respond adequately to biologics. However, their market share remains comparatively lower due to issues like slower onset of action or a less favorable side effect profile.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and conventional DMARDs largely function as adjunct therapies or for symptomatic relief rather than altering disease progression, which limits their dominance in the long-term treatment paradigm. Overall, the shift towards personalized medicine and biologically targeted interventions supports sustained growth and leadership of the biologics segment in the psoriatic arthritis drug class landscape.

By Distribution Channel: Hospital Pharmacies Lead Due to Integrated Care and Access to Advanced Therapies

In terms of By Distribution Channel, hospital pharmacies hold the highest market share within the Psoriatic Arthritis segment, driven primarily by their integral role in delivering comprehensive and multidisciplinary care. Hospitals serve as primary centers for diagnosis, treatment initiation, and management of complex psoriatic arthritis cases, often requiring specialist rheumatologists and access to advanced therapeutic options such as biologics. Given the stringent storage requirements and administration protocols associated with many of these drugs, hospital pharmacies are preferred because they provide controlled environments ensuring proper handling and patient monitoring during treatment initiation.

Moreover, hospital pharmacies typically coordinate with healthcare providers for patient education, adherence support, and management of adverse effects, resulting in improved therapeutic outcomes. The rising prevalence of psoriatic arthritis and increasing awareness among clinicians have prompted healthcare institutions to strengthen their pharmacy services, including stocking a wider range of treatment options and enhancing clinical pharmacy interventions. This expanded service capability has further entrenched hospital pharmacies as a crucial distribution channel.

Although retail and online pharmacies are gaining prominence for ease of access and convenience, particularly for maintenance therapies, they face limitations in managing complex biologic therapies that require specialist oversight. Clinics also contribute to distribution, but often on a smaller scale, focusing on follow-up and maintenance treatments rather than initial dispensing of advanced drugs. The preference for hospital pharmacies thus reflects the necessity for integrated healthcare delivery where diagnosis, treatment, and pharmacological management converge within clinical settings.

By End User: Hospitals Capture Largest Share Due to Comprehensive Care Infrastructure and Specialist Expertise

In terms of By End User, hospitals represent the largest segment for psoriatic arthritis treatment, largely because of their comprehensive infrastructure and availability of specialist expertise essential for managing this multifaceted autoimmune condition. The complexity of psoriatic arthritis, which manifests with both articular and dermatological symptoms, demands coordinated care across various disciplines including rheumatology, dermatology, radiology, and physical therapy. Hospitals provide the ecosystem conducive to such collaborative care pathways, enhancing diagnostic accuracy, treatment customization, and continuous monitoring of disease progression.

Patients with moderate to severe disease are frequently hospitalized or referred to hospital outpatient departments for initiation of advanced therapies, particularly biologics, which require detailed patient evaluation and sometimes pre-treatment screening for infections or comorbidities. The availability of specialized diagnostic tools and treatment protocols within hospitals ensures optimal patient selection and management. Moreover, hospital settings offer access to clinical trials and novel therapies, facilitating early adoption of cutting-edge treatments for eligible patients.

While specialty clinics also contribute significantly by offering focused care, their scale and resource availability often limit extensive multidisciplinary interventions. Homecare settings, though valuable for ongoing drug administration and symptom management, lack the diagnostic and emergency care capabilities inherent to hospitals. Thus, the dominance of hospitals as end users reflects their ability to cater to the full spectrum of patient needs - from diagnosis through complex therapeutic regimens - positioning them at the forefront of psoriatic arthritis care delivery.

Regional Insights:

Dominating Region: North America

In North America, the Psoriatic Arthritis market is dominating due to a well-established healthcare infrastructure, high awareness levels about autoimmune diseases, and significant investment in research and development by pharmaceutical companies. Robust government policies that support expedited drug approvals and reimbursement frameworks further strengthen market growth here. The presence of key industry players such as Pfizer, AbbVie, and Johnson & Johnson has accelerated the development and commercialization of advanced biologic therapies and novel small molecule inhibitors. Additionally, North America's sophisticated patient support programs and widespread clinical trial activities contribute to its leading position in the market. Trade dynamics favor the rapid entry of innovative treatments, and an extensive network of specialized rheumatology clinics ensures broad patient reach.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth in the Psoriatic Arthritis market, driven by increasing healthcare expenditure, expanding patient awareness, and improving diagnostic capabilities. The growing presence of multinational pharmaceutical companies investing in regional manufacturing hubs and clinical trials underpins this growth. Government initiatives aiming at improving chronic disease management and expanding insurance coverage have significantly enhanced patient access to advanced therapies. Emerging markets such as China, India, and South Korea are witnessing increased adoption of biologics and targeted therapies. Additionally, evolving regulatory frameworks facilitating faster drug approvals and a growing healthcare ecosystem, including a rise in rheumatologists and specialty clinics, support this accelerated expansion.

Psoriatic Arthritis Market Outlook for Key Countries

United States

The United States' Psoriatic Arthritis market benefits from a highly developed healthcare system and widespread insurance coverage, enabling broader access to advanced therapies. Major biopharmaceutical companies like Amgen, AbbVie, and Eli Lilly maintain a strong presence, driving innovation in biologic and small molecule therapeutics. The U.S. market also leverages cutting-edge clinical research and patient-centric support programs, which enhance treatment adherence and outcomes.

Germany

Germany plays a pivotal role in the European Psoriatic Arthritis market, supported by a universal healthcare system and stringent regulatory standards that encourage the availability of innovative treatments. Key companies such as Novartis, Roche, and Sanofi have substantial operations in the country, focusing on research collaborations and market expansion. German rheumatology networks facilitate disease awareness and early diagnosis, boosting therapy adoption rates.

China

China's growing Psoriatic Arthritis market is fueled by increasing healthcare infrastructure investments, rising patient awareness, and expanding government insurance schemes. Domestic players like Jiangsu Hengrui Medicine, alongside global entities such as Pfizer and AbbVie, actively participate in clinical research and market outreach. Regulatory advancements in drug approvals and an expanding pool of trained healthcare professionals contribute to enhanced treatment penetration across urban and semi-urban regions.

Japan

Japan continues to lead in the Asia Pacific Psoriatic Arthritis landscape with its advanced healthcare system and high patient awareness. Pharmaceutical giants like Takeda, Astellas Pharma, and Chugai Pharmaceutical dominate the market through innovative drug offerings and strong physician networks. Government policies fostering orphan drug designation and fast-track approvals are instrumental in bringing next-generation treatments to market efficiently.

Brazil

Brazil's market shows strong potential due to government initiatives aimed at improving access to specialty care and biosimilar drugs. Companies such as Eurofarma and Biolab Sanus collaborate with multinational corporations to introduce cost-effective therapies suited to the local market. The expansion of public and private healthcare services, coupled with increased awareness programs, supports growing patient engagement and treatment uptake in the region.

Market Report Scope

Market Segmentation

Drug Class Insights (Revenue, USD, 2020 - 2032)

• Biologics
• Small Molecule Therapy
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Conventional DMARDs
• Others

Distribution Channel Insights (Revenue, USD, 2020 - 2032)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Clinics
• Others

End User Insights (Revenue, USD, 2020 - 2032)

• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• AbbVie Inc.
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• UCB S.A.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Roche Holding AG
• Horizon Therapeutics plc
• Samsung Bioepis Co., Ltd.
• Janssen Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Celltrion, Inc.
• Kyowa Kirin Co., Ltd.